Council of the European Union

Brussels, 21 January 2026
(OR. en)

5588/26
ADD 1

DELACT 8
VETER 9
AGRILEG 8

COVER NOTE

From:	Secretary-General of the European Commission, signed by Ms Martine DEPREZ, Director
date of receipt:	20 January 2026
To:	Ms Thérèse BLANCHET, Secretary-General of the Council of the European Union
No. Cion doc.:	C(2026) 22 annex
Subject:	ANNEX to the COMMISSION DELEGATED REGULATION (EU) .../... amending Delegated Regulation (EU) 2020/688 as regards rules for the movement within the Union of kept dogs, cats and ferrets and other carnivores

Delegations will find attached document C(2026) 22 annex.

Encl.: C(2026) 22 annex

EUROPEAN
COMMISSION

Brussels, 20.1.2026
C(2026) 22 final

ANNEX

ANNEX

to the

COMMISSION DELEGATED REGULATION (EU) …/...

amending Delegated Regulation (EU) 2020/688 as regards rules for the movement within the Union of kept dogs, cats and ferrets and other carnivores

ANNEX

‘ANNEX VII

VALIDITY REQUIREMENTS FOR ANTI-RABIES VACCINATION AND RISK-MITIGATING MEASURES FOR DISEASES OTHER THAN RABIES

Part 1

Validity requirements for anti-rabies vaccinations for dogs, cats, ferrets and other carnivores

1. The anti-rabies vaccine shall comply with the following requirements:

   (a) it must be a vaccine other than a live modified vaccine, and fall within one of the following categories:

      (i) an inactivated vaccine of at least one antigenic unit per dose; or

      (ii) a recombinant vaccine expressing the immunising glycoprotein of the rabies virus in a live virus vector;

   (b) where it is administered:

      (i) in a Member State, it has been granted a marketing authorisation in compliance with Regulation (EU) 2019/6 of the European Parliament and of the Council*, or

      (ii) in a third country or territory, it has been granted an approval or a licence by the competent authority and it meets at least the requirements laid down in the relevant part of the chapter concerning rabies in the *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals* of the World Organisation for Animal Health (WOAH).

---

* Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43, ELI: http://data.europa.eu/eli/reg/2019/6/oj).

2. An anti-rabies vaccination shall fulfil the following conditions:

   (a) the vaccine has been administered by an official veterinarian or an authorised veterinarian as defined in Article 2(1) of Delegated Regulation (EU) [*C(2026) 20*]**, as decided by the competent authority;

   (b) the animal was at least 12 weeks old at the time of the primary vaccination;

   (c) the date of administration of the vaccine is indicated by a veterinarian referred to in point (a), in the appropriate section of the identification document referred to in Article 71(1) of Delegated Regulation (EU) 2019/2035;

   (d) the date of administration referred to in point (c) does not precede the date of identification or the date of reading of the identification means indicated in the appropriate section of the identification document referred to in Article 71(1) of Delegated Regulation (EU) 2019/2035;

   (e) the period of validity of the vaccination starts from the establishment of protective immunity, which shall not be less than 21 days from the completion of the vaccination protocol required by the manufacturer for the primary

vaccination, and continues until the end of the period of protective immunity, as prescribed in the technical specifications of the marketing authorisation referred to in point 1(b)(i), or the approval or licence referred to in point 1(b)(ii) for the anti-rabies vaccine in the Member State or third country or territory where the vaccine is administered.

The period of validity of the vaccination shall be indicated by a veterinarian referred to in point (a) in the appropriate section of the identification document referred to in Article 71(1) of Regulation (EU) 2019/2035;

(f) a revaccination must be considered a primary vaccination if it was not carried out within the period of validity referred to in point (e) of the previous vaccination.

** Publication Office to insert title, OJ and ELI references in due course.

Part 2

Risk-mitigating measures for infestation with *Echinococcus multilocularis*

1. The treatment for infestation with *Echinococcus multilocularis* referred to in Article 53, point (d), and Article 55, point (b)(ii), shall be administered by a veterinarian and shall consist of a veterinary medicinal product:

(a) which contains the appropriate dose of:

(i) praziquantel, or

(ii) other pharmacologically active substances, which alone or in combination, have proven to reduce the burden of mature and immature intestinal forms of *Echinococcus multilocularis* in dogs at least as effectively as praziquantel; and

(b) which has been granted either:

(i) a marketing authorisation in compliance with Regulation (EU) 2019/6 of the European Parliament and of the Council, or

(ii) an approval or a licence by the competent authority in a third country.

2. The treatment referred to in point 1 shall have been administered within a period commencing not more than 120 hours and ending not less than 24 hours prior to the date of the scheduled entry into a Member State or zone thereof with a disease-free status from *Echinococcus multilocularis*.

3. For canidae other than dogs, the treatment referred to in Article 58(1), point (d), against infestation with *Echinococcus multilocularis* shall consist of a veterinary medicinal product referred to in point (1) and shall have been carried out no earlier than 48 hours prior to entry into a Member State or zone thereof with a disease-free status from *Echinococcus multilocularis*.'